DOC1021

BIOLOGICAL2 trials

Sponsors

Diakonos Oncology Corporation

Conditions

Glioblastoma (GBM)Refractory Melanoma

Phase 1

DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma

RecruitingNCT07288112

Diakonos Oncology CorporationRefractory Melanoma

Start: 2026-04-06End: 2033-01-01Target: 35Updated: 2026-07-16

Phase 2

DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)

RecruitingNCT06805305

Diakonos Oncology CorporationGlioblastoma (GBM)

Start: 2025-03-17End: 2032-03-01Target: 180Updated: 2026-07-01

Related Papers

A phase I/II clinical study of DOC1021 (dubodencel) dendritic cell immunotherapy for refractory melanoma.

Journal of Clinical Oncology2026-05-28

Pooled analysis of phase I and expanded access study cohorts of DOC1021 (dubodencel) in combination with chemoradiation for glioblastoma.

Journal of Clinical Oncology2026-05-27

Phase I Clinical Study of DOC1021 (dubodencel) for Adjuvant Immunotherapy of Glioblastoma

medRxiv2026-04-02